AML patients receive cancer drug DCP-001
December 3, 2018DCprime (spin-off VUmc) announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia. This administration marks the official start of the phase 2 study in the ADVANCE-II study. A total of 20 patients with acute myeloid leukemia (AML), a rare form of leukemia, participate in this study. A recently completed phase I study showed that the cancer drug DCP-001, a vaccine based on dendritic cells, is generally safe and capable of triggering an anti-cancer immune response in patients with AML.
Read here the full press release.
More news
Use of Smart ‘swimming cap’, directs people suffering a stroke to right hospital
A smart swimming cap with electrodes can diagnose a stroke in the ambulance, so that a patient receives the correct treatment more quickly.
News
MIT Feasibility subsidy for VU start-up PreActive to adopt AI in Welness app
VU start-up, PreActive, has been awarded the MIT Feasibility Study subsidy of € 20k from Provincie Noord-Holland! With this subsidy funding PreActive will explore the utility and feasibility of incorporating Artificial Intelligence within the PreActive wellness app to help improve & personalise the user experience. Feasibility study of the Wellness app The PreActive Wellness app […]
News
SusPhos received EU funding for upcycling solution
UvA spin-off SusPhos has been selected for the EIC Accelerator funding. They receive a grant and an equity investment from the EU fund for its game-changing solution for upcycling phosphate from waste streams into sustainable products. SusPhos, now based in Leeuwarden, aims to create “urban mines” in Europe to produce phosphate compounds out of waste. […]
News